Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
NCT03748953
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Myeloma
Interventions
DRUG:
Ixazomib
Sponsor
Millennium Pharmaceuticals, Inc.